All News

2018

June

Media Release / Jun 18, 2018

Novartis International AG: Alcon AcrySof® IQ PanOptix® trifocal intraocular lens shows superior visual performance in head-to-head trial post-cataract surgery

Read More
Media Release / Jun 16, 2018

Novartis JULIET trial of Kymriah demonstrates more than one-year durability of responses in adults with relapsed or refractory DLBCL

Read More
Media Release / Jun 15, 2018

Novartis survey uncovers real-world impact of immune thrombocytopenia or ITP, a rare blood disease, on patients' quality of life

Read More
Media Release / Jun 15, 2018

Novartis study of real-world data concludes Jakavi is associated with a reduction in risk of death and dangerous blood clots for patients with rare blood cancer

Read More
Media Release / Jun 15, 2018

Sandoz presents new long-term and switching data for biosimilars Zessly® (infliximab) and Erelzi® (etanercept) in rheumatoid arthritis

Read More
Media Release / Jun 13, 2018

Novartis presents data to advance understanding of the role of IL-17A and reinforce Cosentyx® leadership in spondyloarthritis

Read More
Bernardo Bazet Lyonnet begins his search for a new medicine
Story / Jun 11, 2018

Open resources at Novartis help drive innovation

With external help from Novartis, an Argentinian researcher was able to begin his search for a new medicine for tuberculosis.

Read More
Media Release / Jun 07, 2018

Novartis announces JCO publication of Lutathera® NETTER-1 data showing significantly longer time to deterioration of key quality of life measures in patients with progressive midgut NETs

Read More
Media Release / Jun 03, 2018

Third Novartis Phase III trial shows Kisqali® combination therapy significantly improves PFS in HR+/HER2- advanced breast cancer

Read More
Media Release / Jun 02, 2018

New Novartis data presented at ASCO find nearly half of CML patients treated with Tasigna® remain in remission almost three years after stopping therapy

Read More

Pages

Related Links

Annual Report 2017

Review the strategy and annual performance of Novartis and read letters from our Chairman and CEO.

Learn More